Immusmol: the Small Molecule Antibody Company
Founded in 2012 by immunologist Dr Alban Bessede, ImmuSmol aims at becoming a natural choice for small molecule antibodies within 5 years. Supported by a French group with annual revenues exceeding 1,3 billion euros, the company was established in 2013 in Pessac, France, just a few miles from the famous "Pessac-Léognan" Bordeaux wine estates.
Our focus: antibodies targeting small molecules
ImmuSmol stands for “immunoglobulins [antibodies] against small molecules”. While traditional antibodies only recognize large molecules such as proteins, ImmuSmol designs and develops antibodies capable of targeting low molecular weight entities (<900 Da).
Amino acids, lipids, saccharids, toxins, drugs, … virtually any small molecule can thus be addressed with high affinity and specificity. Fully compatible with existing antibody-based technologies, small molecule antibodies are opening a whole new set of possibilities in research, diagnostics and therapy.
Three core applications
- Research antibodies - ImmuSmol sells validated primary antibodies, for small molecule detection and visualization in cells and tissues.
- Custom services - ImmuSmol offers to raise antibodies targeting small molecules for research, diagnostic and therapeutic applications.
- Diagnostics & Therapy - Three personalized medicine programs based on proprietary small molecule antibodies are currently under development.